Fig. 7: SYCP2 is a predictive biomarker for drug response in patients.

A MD-MBA-231 cells infected with lentiviruses (LV) expressing siSYCP2 or siCtrl were injected intraperitoneally into mice. Mice were given Saline and 50 mg/kg Olaparib. The representative images of IHC staining of SYCP2 of tumor tissues in the tested mice groups were shown (left). Tumor volume was measured over 23 days (right). (p = 0.0005). Created with BioRender.com. B Summarization of subtypes of breast cancer patients in a TOP1i [Sacituzumab Govitecan (IMMU-132)]-treated group. Patients were divided into the SYCP2^high group and the SYCP2^low group. The cutoff 12 value is the median. Representative images of IHC staining of SYCP2 were shown in each group. Numbers of patients’ responses as Partial Response (PR) or Stable Disease (SD) in the SYCP2^high group and SYCP2^low group were shown, Kaplan-Meier curves of patients’ overall survival and progression-free survival were shown on the right. The analysis was done in one-sided comparison. C Summarization of retrospective study in SYCP2 expression in ovarian cancer patients. Patients were divided into the SYCP2^high group and the SYCP2^low group based on the SYCP2 staining results. Representative images of IHC staining of SYCP2 were shown in each group. Numbers of patients’ responses to Platinum Sensitive or Platinum-Resistant/Refractory tumor in the SYCP2^high group and SYCP2^low group were shown. D The scheme of the role of SYCP2 in contributing to HR and drug resistance in cancer. Source data are provided as a Source Data file.